Potentially preventable tuberculosis among HIV-infected persons in the era of highly active antiretroviral treatment

International Journal of Tuberculosis and Lung Disease

Volumn 13, Issue 3, 2009, Pages 355-359

  Pettit, A C ^a   Barkanic, G ^a   Stinnette, S ^a   Rebeiro, P ^a   Blackwell, R ^b   Raffanti, S P ^a,b   Shepherd, B E ^a   Sterling, Timothy R ^a,c  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Comprehensive Care Center ^*  (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Highly active antiretroviral treatment; Human immunodeficiency virus; M. tuberculosis infection; Tuberculin skin testing; Tuberculosis

Indexed keywords

ENFUVIRTIDE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTPATIENT; PRIORITY JOURNAL; SCREENING; TIME SERIES ANALYSIS; TUBERCULIN TEST; TUBERCULOSIS;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COMORBIDITY; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; TUBERCULIN TEST; TUBERCULOSIS, PULMONARY;

EID: 62349129856     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Selwyn P A, Hartel D, Lewis V A, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 1989; 320: 545-550.
2. Lee L M, Lobato M N, Buskin S E, Morse A, Costa O S. Low adherence to guidelines for preventing TB among persons with newly diagnosed HIV infection, United States. Int J Tuherc Lung Dis 2006; 10: 209-214.
3. Golub J E, Saraceni V, Cavalcante S C, et al. The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil. AIDS 2007; 21: 1441-1448.
4. Lawn S D, Wood R. Incidence of tuberculosis during highly active antiretroviral therapy in high-income and low-income countries. Clin Infect Dis 2005; 41: 1783-1786.
5. Lawn S D, Bekker L G, Miller R F. Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. Lancet Infect Dis 2005; 5: 361-373.
6. American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR 2000; 49 (RR-6): 1-51.
7. Fisk T L, Hon H M, Lennox J L, Fordham von R C, Horsburgh C R Jr. Detection of latent tuberculosis among HIV-infected patients after initiation of highly active antiretroviral therapy. AIDS 2003; 17: 1102-1104.
8. Menzies D, Pai M, Comstock G. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann Intern Med 2007; 146: 340-354.
9. Sterling T R, Bethel J, Goldberg S, Weinfurter P, Yun L, Horsburgh C R. The scope and impact of treatment of latent tuberculosis infection in the United States and Canada. Am J Respir Crit Care Med 2006; 173: 927-931.
10. Elzi L, Schlegel M, Weber R, et al. Reducing tuberculosis incidence by tuberculin skin testing, preventive treatment, and antiretroviral therapy in an area of low tuberculosis transmission. Clin Infect Dis 2007; 44: 94-102.
11. Girardi E, Sabin C A, d'Arminio M A, et al. Incidence of tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America. Clin Infect Dis 2005; 41: 1772-1782.
12. Holt E. Epidemiologic profile of reported tuberculosis in Tennessee, 2005. Nashville, TN, USA: Tuberculosis Elimination Program, Tennessee Department of Health, 2006.
13. Hammer S M, Eron J J Jr., Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel 1. JAMA 2008; 300: 555-570.